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Background: Tinnitus is a result of hyper-activity/hyper-synchrony of auditory neurons coding the tinnitus frequency,
which has developed to synchronous mass activity owing the lack of inhibition. We assume that removal of exactly these
frequency components from an auditory stimulus will cause the brain to reorganize around tonotopic regions coding
the tinnitus frequency. Based on this assumption a novel treatment for tonal tinnitus - tailor-made notched music
training (TMNMT) (Proc Natl Acad Sci USA 107:1207–1210, 2010; Ann N Y Acad Sci 1252:253–258, 2012; Frontiers Syst
Neurosci 6:50, 2012) has been introduced and will be tested in this clinical trial on a large number of tinnitus patients.
Methods and design: A randomized controlled trial (RCT) in parallel group design will be performed in a
double-blinded manner. The choice of the intervention we are going to apply is based on two “proof of concept”
studies in humans (Proc Natl Acad Sci USA 107:1207–1210, 2010; Ann N Y Acad Sci 1252:253–258, 2012; Frontiers Syst
Neurosci 6:50, 2012; PloS One 6(9):e24685, 2011) and on a recent animal study (Front Syst Neurosci 7:21, 2013).
The RCT includes 100 participants with chronic, tonal tinnitus who listened to tailor-made notched music (TMNM) for
two hours a day for three months. The effect of TMNMT is assessed by the tinnitus handicap questionnaire and visual
analogue scales (VAS) measuring perceived tinnitus loudness, distress and handicap.
Discussion: This is the first randomized controlled trial applying TMNMT on a larger number of patients with tonal
tinnitus. Our data will verify more securely and reliably the effectiveness of this kind of completely non-invasive and
low-cost treatment approach on tonal tinnitus.
Trial registration: Current Controlled Trials ISRCTN04840953
Keywords: Tinnitus, Tailor-made notched music training (TMNMT), Münster Tinnitus randomized controlled Clinical
Trial-2013Background
Over the past 15 years, we have studied the plasticity of
the human auditory cortex by means of magnetoenceph-
alography (MEG). Two main topics nurtured our curios-
ity: the effects of musical training and the effects of
lateral inhibition. Our studies demonstrated that short-
term and long-term musical training was able to induce
functional plasticity changes in the human auditory cor-
tex. Listening to notched music for three hours inhibited* Correspondence: pantev@uni-muenster.de
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reproduction in any medium, provided the orthe neuronal activity in the auditory cortex that corre-
sponded to the center frequency of the notch [1]. In a
previous MEG study we have investigated the masking
effect on a certain frequency region of the human audi-
tory cortex [2] as based on quasi-simultaneous perform-
ance of habituation and lateral inhibition. Crucially, the
overall masking effect on human auditory cortical activity
was stronger in case of lateral inhibition than in case of ha-
bituation. We recently brought our findings and ideas to-
gether to develop a novel treatment strategy for tonal
tinnitus - tailor-made notched music training (TMNMT)
[3-6]. By notching the music energy spectrum around theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ition to auditory neurons involved in tinnitus perception.
The contemporary view on tinnitus biology is that al-
though tinnitus may be triggered by injury to the inner
ear, the neural generators are most readily found centrally,
and while the neural generators may be primarily auditory,
non-auditory centers often participate. Studies of noise-
induced tinnitus have given rise to the general theory that
tinnitus is triggered by injury to inner ear hair cell popula-
tions. The consequence is a lack of lateral inhibition from
the primarily damaged frequency areas, which leads to
augmented excitation in the spectral neighbor’s regions of
the lesion. This change causes plastic adjustments in the
central auditory system that culminates in alterations of
spontaneous activity. The theory also holds that central
auditory system plasticity is the main centerpiece of these
adjustments, whereby reduced auditory nerve input trig-
gers a shift in the balance of excitation and inhibition cen-
trally [7]. This shift leads to the emergence of a tripartite
complex of changes that includes hyperactivity, increased
bursting activity, and increased synchrony. Such changes
reflect a loss of inhibitory drive to neurons, particularly of
glycinergic and GABAergic systems, but increases in exci-
tation via upregulations of glutamatergic and cholinergic
systems [8-11]. This view is consistent with the three-
faceted nature of tinnitus, which includes auditory, atten-
tional, and emotional components.
Based on the above theory, tinnitus is a result of hyper-
activity/hyper-synchrony of auditory neurons coding the
tinnitus frequency, which has developed to synchronous
mass activity owing the lack of inhibition. It can be as-
sumed that removal of exactly these frequency compo-
nents from an auditory stimulus will cause the brain to
reorganize around tonotopic regions coding the tinnitus
frequency. Based on this assumption, a novel treatment
for tonal tinnitus has been introduced and evaluated in
two controlled blind studies [3,6]. The auditory stimulus
was the favorite music as chosen by the individual patient
in order to increase the positive attention. However, the
music was filtered to exclude a range around the individ-
ual’s tinnitus frequency. To monitor the effectiveness of
this treatment, a behavioral self-report measure was used
in addition to two neuro-physiological measures of ac-
tivity of the auditory cortex: the Auditory Steady State
Response (ASSR), representing primary auditory cortex
activation, and the N1m response, representing activity of
secondary auditory cortical areas. After 6 and 12 months of
TMNMT, clear effects of the therapy have been obtained.
The tinnitus frequency showed a significant decrease in
both the behavioral and the physiological responses com-
pared to controls. The subsequent short-term (5 days)
training study [6] indicated that training was more effective
in the case of tinnitus frequencies ≤ 8 kHz compared to tin-
nitus frequencies > 8 kHz, and that training should beperformed over a long-term period in order to induce more
persistent effects. This phenomenon could be explained by
attraction of lateral inhibition to the neurons coding the
tinnitus frequency, which they obtain from those neurons
coding frequencies above and below the tinnitus frequency.
This mechanism explains the alleviation of the tinnitus
perception and thus the improvement reported by the
tinnitus patients.
Based on the findings of and ideas triggered by those
studies, we further developed both the training stimulus
and the training strategy in order to maximize their effi-
cacy. Thus, this refined, completely non-invasive, and rela-
tively low-cost treatment approach to tonal tinnitus will
be evaluated in a randomized controlled clinical trial on a
larger cohort of tinnitus patients.
Methods/design
Trial design
This will be a Randomized Control Trial (RCT) in paral-
lel group design. RCTs are the gold standard for evaluat-
ing the efficacy of a treatment intervention [12] and our
RCT will be performed in a double-blinded manner in
order to control for non-specific and placebo effects.
The choice of the intervention we are going to apply is
based on “proof of concept” studies in humans [3-6] and
on a recent animal study [13].
We will investigate a target and a placebo group. Using
a placebo treatment as a control condition serves to differ-
entiate specific effects of an intervention from non- spe-
cific effects like expectation, anticipation, patient care, the
investigator's attention, as well as plain listening to music
and the accompanied relaxation or spontaneous improve-
ment. The treatment will last 3 months, with two succes-
sive hours of TMNMT per day (ca. 180 hours of training
in total). The target and placebo groups will receive the
corresponding treatments as described below.
The clinical trial design is graphically presented in
Figure 1. Participants are recruited in an entry examin-
ation. The procedure is described below. On the second
date (baseline) participants are informed about the clinical
trial and are instructed how to perform a pitch matching
of their tinnitus during the following week. On the third
(pre) date, two weeks later, participants are finally selected
for the trial. The decision is based on a reliable perform-
ance on the pitch-matching task. Participants are then
provided with the music treatment. Primary and second-
ary outcome measures are collected at baseline, initially
before treatment starts (pre), at the end of the treatment
(post) and at one-month follow-up. Trend measurements
consist of the primary outcome measures.
Participants (inclusion and exclusion criteria)
The participants (estimated N = 100) are recruited
by means of advertisements in local newspapers, our
Figure 1 Tinnitus clinical trial design.
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the University of Münster and by the distribution of flyers
to local ENT practitioners. We overtly communicate the
study criteria through homepages and flyers. Additionally,
potential participants are asked to answer a questionnaire
covering questions like the characteristics, duration, onset,
possible cause, and treatment of the tinnitus as well as
pre-existing illnesses, hyperacusis, current medication and
drug consumption. According to the questionnaire, the
participants are scheduled for a multidisciplinary entry
investigation in the ENT department of the University
Hospital Münster. This procedure lasts for approximately
two hours. It starts with a screening by psychologists who
explore in depth the occurrence, the development, and
the treatment of the tinnitus as well as the criteria already
specified in the questionnaire described above. Further-
more, tinnitus is assessed by means of standardized ques-
tionnaires (Tinnitus Handicap Questionnaire (THQ) [14],
Tinnitus Handicap Inventory (THI) ([15] German transla-
tion), and VAS). Psychological assessment is additionally
supported by psychometrical data of a depression scale
(Allgemeine Depressionsscala – Langfassung, ADS-L) [16]
and the Symptom Checklist to capture general psycho-
logical distress (SCL-90-R) [17]. After psychological as-
sessment, a physical examination of the ear is performed
by an ENT physician. Additionally, hearing thresholds of
the tinnitus patients are measured via an audiometric pro-
cedureusing a clinical audiometer (Type Madsen Astera,
Denmark) that is able to operate in an extended frequency
range up to 16 kHz.
The patients recruited for the clinical trial will meet all
inclusion criteria. In case of bilateral tinnitus, the dom-
inant tinnitus frequency should not differ between ears
according to patients’ reports.Inclusion criteria
1. (i) Patients with chronic (≥ 3 months) tonal (i.e.
peep- or whistle-like) tinnitus with (ii) dominant
tinnitus frequencies between 1 and 12 kHz, and (iii)
without severe hearing loss (≤ 70 dB HL) in the
frequency ranges of one half octave above and below
the tinnitus frequency.
2. Aged between 18 and 70 years.
3. Written informed consent to participate in the trial.Exclusion criteria
1. Report of severe or acute neurological or psychiatric
disorders (e.g. amnesia, dementia, epilepsy, etc.) that
could limit their capability or that could result in
major difficulties regarding the patients’ motivational
compliance, their ability to follow instructions or to
participate in the training.
2. Tinnitus patients with acute otological diseases.
3. Planned start of other rehabilitation therapies that
might interfere with this trial, participation in another
clinical trial, or insufficient motivation to participate.Drop-out criteria
Participants are declared as “drop-outs” if they indicate
that they do not want to continue the TMNMT. If pa-
tients experience increase of tinnitus loudness or state to
hear an additional tone after they listened to the music for
at least eight weeks, we advise them to stop their partici-
pation in the training. Nevertheless, we ask participants
who stop performing the training to continue completing
questionnaires.
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sample increases the chances to find an effective inter-
vention, but the generalizability of the results is reduced
since the study population is no longer representative of
the majority of tinnitus patients [18].Music spectrum treatment
The patients from target and placebo treatment groups
provide their favorite music (10 CDs). The music will then
be modified “on-line” in several successive steps. First, the
energy spectrum of the music will be “flattened”, i.e. the
amplitude of the music frequency spectrum in the low
and high frequency range will be equalized by redistribu-
tion of energy from low to high frequency ranges. This
should guarantee an equal amount of spectral power
below and above the frequency area suppressed by the
notch filter. Second, the fre-quency band of 1/2 octave
width centered at the individual tinnitus frequency will be
removed from the music energy spectrum. Third, the
edges of the notch will be amplified within the width of
3/8 octaves on each side of the notch by 20 dB SL [19].
All three procedures are aimed at increasing the lateral
inhibition effect within the notch area corresponding to
the tinnitus frequency (c.f. Figure 2). The performance
of the individual TMNMT procedure as described in
our “proof of principle” papers will be performed ac-
cording to one of two protocols: (i) target (fixed notch)
or (ii) placebo (moving notch) and is realized on a mo-
bile device, which provides a tremendous advantage
allowing to perform the TMNMT at home.Target condition
In the target condition, the frequency band centered at
the individual tinnitus frequency of each tinnitus patient
is removed from the music energy spectrum, and theFigure 2 Music spectrum modification.music is modified due to changes described above. The
music is delivered to both ears simultaneously and modi-
fied identically. The patients listen to their individually
modified treatment music daily in a quiet environment via
supplied closed headphones (model: Sennheiser HD 201)
with convenient loudness over the course of 3 months. Pa-
tients are told not to listen, if possible, to normal, non-
modified music during the treatment phase. Listening
times and duration are documented on a daily basis by a
specially developed iOS application. The obtained data are
sent to the tinnitus research team as an email attachment
every week.Control (Placebo) condition
In the placebo condition, a moving notch filter having
the same bandwidth as in the target condition but omit-
ting the tinnitus frequency region is applied. The moving
filter randomly chooses a frequency band outside of
the tinnitus frequency region. After 5 s of filtering,
the center frequency of the filter randomly jumps either
1/18 octave up or down and continues jumping in the
same direction every 5 s until its lower or higher edge
reaches a predefined border, at which point it changes
direction.Assessment of the tinnitus frequency
We adapted a recursive two-interval forced choice
estimation of the tinnitus frequency [20,21], which is
as good as the clinical audiometry testing, but it can
be performed in one third of the time [22]. The frequency
range (1 to 16 kHz) is bisected into two equally large
subintervals. For both, the low and the high fre-
quency subinterval, the participant has to choose whether
the tinnitus is more similar to its lower or higher fre-
quency end.
Depending on the outcome, bisection and two-interval
forced-choice testing are reapplied to the low subinter-
val, the high subinterval, or a new middle interval that is
bound by the midpoints of the low and the high subin-
terval [20,21]. Prior to testing, the left or right ear is se-
lected. Loudness of the test tones is adjusted individually
by participants to match the tinnitus loudness and saved
by the application. A two-alternative forced-choice octave
confusion test completes the testing. All choices made by
participants are saved in an ASCII table file. Participants
perform the pitch-matching test at home two times a day
over five days. Frequencies are transformed into Cent.
The Cent is a logarithmic unit of measure used for mu-
sical intervals. Twelve-tone equal temperament divides
the octave into 12 semitones of 100 cent each. With the
frequency in Cent the arithmetic mean of the ten mea-
surements is calculated as the final tinnitus frequency for
the treatment.
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To perform the necessary modification of the music
(TMNMT), software which performs the three successive
steps (described above) has been developed. In the target
condition, the investigator has to set up a center frequency
and a bandwidth of the notch filter and choose a band-
width for the amplified notch edges. These parameters are
entered via a graphical user interface provided by the soft-
ware application. In the placebo condition, the settings are
defined using the same graphical user interface.
Instructions for subjects during TMNMT
Subjects are instructed to listen to the music attentively
in a quiet surrounding at home with comfortable loud-
ness. They are allowed to read, surf the internet or do
other relaxing activities. Any cognitive or attention de-
manding task, such as working or learning, should be
avoided. Additionally, there should be no sound distrac-
tions during TMNMT, such as telephone or alarm bell
ringing, conversations etc.
Outcome measures
Since tinnitus is a purely subjective percept, the definition
of outcome measurements is challenging [18]. Compre-
hensive assessments of tinnitus would ideally address four
subjective principal components: (1) auditory features of
the tinnitus percept including loudness and pitch, (2)
emotional distress, (3) attentional features like awareness
of tinnitus in daily life and (4) behavioral influence. Separ-
ate assessment of these different components is especially
relevant, since they correlate only relatively weakly with
each other [23]. The primary efficacy endpoints are sig-
nificant reductions in tinnitus loudness, annoyance, aware-
ness and handicapping scores at the end of the training
after 3 months compared to baseline. These parameters
are monitored throughout the study, i.e. prior to TMNMT
start (baseline), during TMNMT (treatment), after TMN
MT (post) and one month after TMNMT (follow-up) (c.f.
Figure 1).
Primary outcome measures
(i) Tinnitus-related distress is assessed with the THQ
([7] German translation). For statistical analyses, the
total score will be used.
(ii) VAS total score. Participants will rate their tinnitus
loudness, annoyance, awareness and handicap by
VAS (scale from 0 to 100). The mean score from
these four scales will be used as the total score.
Secondary outcome measures
Following the suggestion of Landgrebe et al. [18] we in-
clude the THI ([15] German translation) for better com-
parability among clinical trials in tinnitus. Additionally,the German version of the Tinnitus Questionnaire (TQ)
[24,25] will be used as secondary outcome measures. Fur-
thermore, the emotional and cognitive distress subscale
of the THQ [14] and the subscales of the VAS will be
analyzed.
To allow further sub-group analyses, we will collect the
following data: ADS-L, SCL-R-90, German hyperacusis
questionnaire (Geräuschüberempfindlich-keits-Fragebogen,
GÜF), listening duration of TMNM, average listening
duration of conventional music, VAS measuring differ-
ent aspects of listening to TMNM (enjoyment, relax-
ation, attention to the music), subjective expe-rience
with TMNMT (improvement of tinnitus, recommenda-
tion of TMNMT) and side effects of TMNMT.
To evaluate the time course of subjective tinnitus changes
we will measure the subjective tinnitus loudness, annoy-
ance, distress, and handicap status by means of VAS
throughout the study on two days per week (Wednesday
and Sunday) beginning fourteen days prior to TMNMT on-
set and ending 31 days after TMNMTcompletion. The par-
ticipant is reminded to do those ratings via the calendar
function of the provided mobile device twice a week, every
Wednesday and Sunday at 12:00 o’ clock.Sample size
During the planning state, a priori power calculations
were used to estimate an adequate sample size to find
meaningful clinical changes in our outcome variables. The
calculations were performed using G*Power3.1.5 [26]. The
estimation of the expected effect size was based on an ap-
proximation rule of thumb about the minimal clinically
important differences proposed by Norman et al. 2003
[27]. In their systematic review of 38 studies, they found
that the threshold to determine a clinical relevant change
in health-related questionnaires was approximately 0.5
standard deviations [27]. This corresponds to a standard-
ized effect size of d = 0.5 which can be interpreted as a
medium effect [26]. The conventions for effect sizes of re-
peated measures ANOVAs were defined by Cohen [28] as
f = 0.1, f = 0.25 and f = 0.4 for small, medium and large ef-
fects, respectively. Thus, we chose a medium effect size of
f = 0.25 for our power analysis to assure that we are able
to detect the assumed minimal clinically important differ-
ence. We planned to achieve a power of .90 for testing the
interaction effect Time (pre, post) × Group (placebo,
treatment) (5% significance level). The correlation be-
tween the two repeated measures was set to r = 0. Note
that this reflects a conservative approximation and any
correlation larger than r = 0 would reduce the required
amount of participants. Due to these assumptions, a sam-
ple size of N = 88 resulted as necessary. To take into ac-
count an anticipated dropout rate of 13%, the final sample
size will be set to N = 100, i.e. 50 participants per group.
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As of now, we are planning to investigate 100 patients
with tonal tinnitus (see recruitment criteria above) in
two study arms:
(iii) Target group, 50 tonal tinnitus patients with
tinnitus frequency (TF) < = 12 kHz obtaining
TMNMT
(iv) Control group, 50 tonal tinnitus patients (TF < =
12 kHz) obtaining placebo treatment.
The allocation to the two groups will be done using
stratified randomization. Stratification is an appropriate
allocation method for improving power in small trials
(< 400 patients) and preventing type 1 errors [29]. It
was proposed to use a minimum number of strata to
improve statistical efficiency, since this allows the assign-
ment of an equal number of subjects to each treatment
and assures an equal distribution of the stratification factor
between groups [29,30]. We choose the variables age (< 51
or > = 51 years) and hearing loss (< 40 dB or > = 40 dB)
[31,32] as stratification categories to keep the number of
strata minimal (n = 4) but include the two variables most
probable to influence the treatment outcome. Within each
stratum, a blocked randomization will be performed using
a computer generated randomization list. To ensure that
study results are not confounded by anticipation or ex-
pectation, both the participants and the investigators will
be blind to the allocation.
Whether the participant receives placebo or real treat-
ment is determined by the settings of the TMNMT-App
on the iPod touch mobile device. An external person,
not involved in the Clinical Trial, is responsible for the
allocation of each participant to one of the two groups
(treatment or placebo) and sets up the App according to
that. Afterwards, the App is locked and password-secured
to disable further changes and the iPod is handed back to
the original investigator.
Statistical methods
The statistical analysis for this clinical trial will be per-
formed at the Institute for Biomagnetism and Biosigna-
lanalysis. The respective hypotheses are formulated as
one-sided [3-6]. In an intention-to-treat analysis the data
of all participants that were assigned to the treatment or
to the placebo group will be analyzed statistically. In an-
ticipation of dropouts and missing data, a likelihood-
based mixed-effects model for repeated measures analysis
[33] was chosen as the primary analysis.
Additionally, we will run an analysis with complete
cases. This will be done by means of repeated measures
ANOVAs and planned comparisons; post-hoc analysis
will be corrected for multiple testing, if necessary. In order
to rule out adverse effects of the treatment and to preventfutility, an interim analysis will be conducted after 50% of
the participants completed the training (post measure-
ment). For this purpose data will be unblinded and stored
in a way that no inference to the single participant can be
made (e.g. without age, gender, hearing loss, etc., only ana-
lysis relevant data (group and outcome measures)). The
storage is done by an external person, who is also respon-
sible for blinding, and the analysis is carried out by the
investigators.
In case of a significant interaction between group and
primary outcome measures revealing a negative effect
for the treatment group, the trial will be stopped.
Reporting of trial results
The last and very important step in planning and con-
ducting a clinical trial is to report the results (even if
negative). We further agree that publishing results from
clinical trials is essential in order to inform the scientific
community of what was done and what the results are.
Therefore, it is necessary that negative results should
also be published.
Furthermore, it is opinion that the results of the clinical
trial should be published following a common scientific
standard set by the CONSORT Group (“consolidated stan-
dards of reporting clinical trials” http://www.consortstate
ment.org) [34,35]. The main objective of CONSORT is to
facilitate critical appraisal and interpretation of RCTs by
providing guidelines on how to report methods and results
of a RCT. We are informed that the methodological
details, which are required to be reported, are summarized
in the CONSORT statement and checklist (http://www.
consort-statement.org/consort-statement).
Ethical aspects of the clinical trial
The ethical aspects of the clinical trial were reviewed by an
independent Institutional Review Board (Ethical Commis-
sion of the University of Münster) and an ethical approval
was obtained before the trial starts. In addition, according
to Good Clinical Practice-(GCP)-Guidelines, the partici-
pants in the clinical trial are fully informed about the na-
ture, benefits and potential dangers of the trial as well as
alternative treatment options, and they have to sign an in-
formed consent form before they can be enrolled into the
study (c.f. the information and consensus forms). If the
target treatment is effective and superior to placebo, the
patients of the placebo group will be offered the target
treatment after completion of the trial.
Discussion
This is the first randomized controlled trial on a larger
number of patients with tonal tinnitus applying the TM
NMT. Our data will verify more securely and reliably the
effectiveness of this kind of completely non-invasive and
low-cost treatment approach on tonal tinnitus.
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